Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy

Zil Goldstein, Musaub Khan, Tamar Reisman, Joshua D Safer

1Center for Transgender Medicine and Surgery at Mount Sinai, Mount Sinai Health System and Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; 2New York Medical College, Valhalla, NY USA

Introduction: Venous thromboembolism (VTE) is a known risk of hormone therapy. This risk has been well established in the gynecologic literature, specifically in studies of combined oral contraceptives (COCs) and postmenopausal hormone regimens in the cisgender woman.1 However, the nuances of VTE risk in transgender individuals using hormone therapy are poorly understood.

Many transgender people use hormone therapy to change their bodies to be more congruent with their gender identity. Data consistently show a significant improvement in the quality of life for transgender people who initiate hormone therapy, which is essential in a population that shows incredibly high rates of attempted suicide.2,3 For example, transgender people utilizing hormones reported
lower rates of anxiety relative to those not using hormones, and rates decreased enough to be comparable to the general population. For trans masculine individuals, those whose sex was recorded female at birth and who identify as men, this involves administration of exogenous testosterone, and data available to date show no increased risk of VTE among these individuals. Therefore, this review will focus largely on trans feminine individuals, those whose sex was recorded male at birth and who identify as women, where the usual hormone regimens include combinations of estrogens and antiandrogen therapies. Many trans feminine people choose to use feminizing hormone therapy despite possible increased VTE risks. Understanding the risks of hormone therapy for transgender people is essential under these circumstances so clinicians can best guide their patients in identifying and minimizing VTE risks while also improving the quality of trans feminine individuals’ lives.

Complicating the interpretation of the available data are considerations regarding the degree that age, estrogen route of administration, and patient comorbidities may affect the VTE risk. Many of the studies do not control for these risk factors.

Methods
In accordance with the PRISMA guidelines, we searched PubMed using the terms “transgender”, “estrogen”, “VTE”, and “HRT” (hormone replacement therapy) both through the standard search engine and using MeSH search combinations. From these combinations, we initially found 6,349 studies. We excluded studies that related to the effects of hormone therapy in postmenopausal women and women on birth control, as well as studies that did not analyze the relationship between thromboembolic events and hormone replacement therapy in trans feminine and trans masculine individuals. As a result, the inclusion criteria included studies that mentioned the type of hormone utilized, the route of administration, and patient comorbidities to more comprehensively understand the risk of VTE. We discovered 13 studies between 1989 and 2018 that investigated the effects of hormone therapy, including thrombotic events, in transgender women and men.

Hormone therapy for cisgender people: venous thromboembolism and estrogen
With few data directly examining the effects of hormone therapy on transgender people, some guidance may be drawn from the available data in cisgender (nontransgender) individuals which focuses on hormonal birth control and postmenopausal hormone replacement therapy.

Hormonal contraceptives
Most hormonal contraceptives fall into a category termed “combined oral contraceptives” (COCs) which contain a combination of ethinyl estradiol and a progestin. Colloquially, this medication is referred to as “the pill”. COCs vary in estrogen dose and progestin formulation. Progestins, in particular, can vary in their estrogenic, anti-estrogenic, progestational, antiandrogenic, and androgenic properties. The first documented cases of VTE were published in the 1960s. Over subsequent years, the link between hormonal contraceptives and VTE has been solidified.

The risk for embolic events in hormonal contraceptive users has been estimated at 3–9 per 10,000 woman-years vs 1–5 per 10,000 woman-years in nonusers. The use of oral contraceptive drugs increases the risk of VTE 3.8-fold (95% CI 2.4–6.0). However, the increased risk of VTE attributable to hormonal contraceptives varies depending on the estradiol dose and progestin type. The highest risk period for VTE occurs with new COC use and in women starting or restarting COC after prolonged discontinuation. Progestin-only pills are not associated with increased VTE risk.

The initial COCs in the 1950s contained a relatively high ethinyl estradiol content with 50 µg per pill. Newer pills contain less ethinyl estradiol, but still may be associated with a higher risk of VTE. Pills containing the third-generation progestagen desogestrel have a relative risk of VTE of 8.7 compared to 2.2 and 3.8 for COCs with other types of progestogens, such as levonorgestrel. COCs with 30 µg of ethinyl estradiol and desogestrel have an age-adjusted relative risk of 2.5 (95% CI 1.2–5.2) compared to other COCs, like levonorgestrel.

In particular, the elevated VTE risk associated with drospirenone-containing COCs has been the subject of much debate. Drospirenone is a progestogen that is similar in structure to spironolactone with antimineralocorticoid and antiandrogen effects. Two large European studies demonstrated that, when compared to women taking COCs with levonorgestrel, women taking drospirenone-containing COCs suffered a significantly higher rate of VTE. This finding was thought to be related to the observation that aldosterone modifies hemostasis and leads to decreased coagulability. In light of the apparent connection between drospirenone and VTE, the US Food and Drug

1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20.
Administration (FDA) released a statement indicating that COCs containing drospirenone may be associated with a higher risk of VTE compared to other COCs, although the FDA did not establish causality. A subsequent FDA-funded study published in 2011 came to similar conclusions as the European trials. By contrast, three large prospective cohort studies, including the European Active Surveillance Study, a US study of 67,000 new COC users, and the International Active Surveillance Study of Women Taking Oral Contraceptives, showed no difference in VTE risk in drospirenone-containing COCs compared to other COCs. Moreover, women who took 24-day regimens of drospirenone-containing COCs had lower pregnancy rates with typical use than users of 21-day regimens of other progestin-containing COCs.

To put the above findings into perspective, it is important to note that despite the increased risk of VTE in women treated with COCs compared to nonusers, the VTE risk associated with COCs is minimal compared to the risk associated with pregnancy and the postpartum period. Pregnancy is associated with a VTE risk of 5–20/10,000 woman-years, and the postpartum period with a risk of 40–65/10,000 woman-years. Physiologic changes occurring during pregnancy include an increase in coagulation factors and fibrinogen, as well as a decrease in anticoagulants.

The decision to start a patient on hormonal contraception must take into account that individual’s personal risk factors for VTE. In particular, much work has been done on characterizing the risks associated with the factor V Leiden mutation. Compared to women not using the oral contraceptive pill and without factor V leiden mutation, the risk of women with factor V leiden mutation who also took the pill was 29-fold higher.

Additional high-risk factors for VTE in COC users include the following:

- Smoking and age >35 years
- Less than 21 days postpartum or 21–42 days postpartum with other risk factors
- Major surgery with prolonged immobilization
- History of deep vein thrombosis or pulmonary embolism
- Hereditary thrombophilia (including antiphospholipid syndrome)
- Inflammatory bowel disease with active or extensive disease, surgery, immobilization, corticosteroid use, vitamin deficiencies, or fluid depletion
- Systemic lupus erythematosus with positive (or unknown) antiphospholipid antibodies

In the above clinical scenarios, the use of hormonal contraception is contraindicated. For other women, the risk of VTE must be balanced with the benefits provided by hormonal contraception such as treatment of menstrual disorders and protection against unwanted pregnancy.

**Menopausal hormone replacement and VTE**

Postmenopausal vasomotor symptoms were the first indication for treatment with exogenous estrogen. In 1942, the FDA approved the first exogenous estrogen product, Premarin (a conjugated equine estrogen (CEE)), isolated from pregnant horse urine for the treatment of “hot flashes” associated with menopause.

The Women’s Health Initiative was a large observational study conducted by the National Institutes of Health in the 1990s and early 2000s to address health outcomes associated with postmenopausal HRT. Over its course, the study enrolled more than 160,000 women and had a budget of $625 million. Postmenopausal HRT users were found to have 34 clotting events annually per 10,000 women vs nonusers who had a risk of 16 events per 10,000 women. This risk persisted throughout the study and was less apparent in women using estrogen only (meaning they had undergone hysterectomy and thus did not require treatment with progestin to prevent endometrial cancer). Ultimately, the estrogen/progesterone arm of the Women’s Health Initiative study was terminated early in 2002 due to concerns of adverse effects.

The Women’s Health Initiative used oral conjugated estrogens (Premarin) and medroxyprogesterone acetate in its estrogen/progesterone arm, which is of specific interest when discussing VTE risk. It is now thought that the method of estrogen administration impacts VTE outcomes. The ESTHER (Estrogen and Thromboembolism Risk) study suggested that oral, but not transdermal, estradiol increases the risk of VTE in postmenopausal women. Oral estrogens have a significant first-pass effect, which is possibly what causes their disproportionate thrombogenic effects. Oral estrogen increases levels of factor VII, factor VIII, factor X, prothrombin, and fibrinogen, and decreases antithrombin and protein S. However, available data compare nonequivalent doses of transdermal and oral estrogens, so it is unclear whether this is dose related or route of administration related.

**Transgender women and HRT**

Analysis of the noted studies suggests that the type of oral estrogen, hormone route of administration, and patient...
demographics and comorbidities may affect estrogen’s link with VTE (Table 1). The data also suggest that myocardial infarction is less frequently observed than stroke, and venous disease is most prevalent.5,33,34

Different types of estrogen may be associated with different risk profiles. Ethinyl estradiol, the most common estrogen in COC pills, has the most data suggesting a link to VTE. A long-term retrospective study following hormone treatments in 966 transgender women for a median of 18.5 years found that oral ethinyl estradiol is independently associated with a 3-fold increase in cardiovascular death, including by VTE.9 A cohort study of 816 transgender women further found venous thromboembolic incidents in 41 patients (5.5%), with 40 of those individuals taking oral ethinyl estradiol and one prescribed transdermal estrogen with a prior history of VTE.8

By contrast, CEEs and 17β-estradiol appear much safer. A cohort of 61 transgender women who were prescribed CEEs did not suffer any venous thromboembolic events, and neither did another group of 23 transgender women who were taking an oral estradiol regimen.34 In one study, however, it was shown that CEEs were correlated with a higher VTE risk than estrogen valerate or ethinyl estradiol.35 While these data suggest the relative safety of various oral estrogens relative to ethinyl estradiol, more complete trials need to be conducted to further understand their safety. However, it seems the case that different oral estrogens do offer varying risk for transgender women, and this is important to consider when evaluating the cardiovascular risk of hormone therapy.

Transdermal estrogen, whether patch or gel, has been reported to have the least thrombogenic profile in transgender women, although there are no head-to-head studies with other estrogen products. In a study of 162 transgender women prescribed transdermal estrogen for an average of 4.4 years, no VTE occurred.36 This is particularly significant as 18 study participants were identified to have thrombophilic genetic mutations at the initiation of hormone therapy.

Oral estrogens seem to have similar effects on surrogate endpoints in transgender women as they do in cisgender women. In 23 transgender women taking Premarin over a span of 6 months, proinflammatory cytokines IL-1, IL-6, IL-8, and tumor necrosis factor-α were elevated.37 Transdermal estrogen, on the other hand, has not been reported to increase proinflammatory cytokines and procoagulant factors, and this is further corroborated in transgender women.37–39

The pharmacokinetics of transdermal and oral estrogen could support a model where transdermal estrogens are safer. However, studies to date do not consider serum estradiol levels or doses of estrogens used as a potential contributing risk factor for VTE. All available data use nonequivalent doses of oral and transdermal estradiol when making these comparisons. Clinicians often use doses up to 0.2–0.3 mg/day of transdermal estradiol, and the highest dose studied is 0.1 mg/day.

Patient demographics and comorbidities also affect their venous thromboembolic risk profile, including age, smoking habits, hypertension, thrombophilic conditions, history of thromboses, and mental illness, among others.

Many of the studies analyzed report coexisting conditions that increase the study participants’ risk for VTE. Variables that have been noted to exacerbate VTE risk include smoking, HIV, malignancies, high cholesterol, clotting disorders, and hypertension. One study showed that all 11 patients who suffered thromboembolic phenomena were smokers, underwent recent surgery, and/or suffered from dyslipidemia or hypertension.5 Only one study to date demonstrates an occurrence of VTE in the absence of risk factors beyond hormone therapy.30

The duration of hormone use has been associated with an increased risk of VTE. The largest retrospective study to date found that among the 61 cases (2% of the trans feminine people on estrogen therapy in the cohort) who experienced VTE, there was a 4-fold risk increase in the women who had been taking estrogen for 8 years compared to those who had been taking estrogen for 2 years.33 This study controlled for smoking status, blood pressure, and history of cardiovascular events but did not address HIV, which could be a possible confounding variable between these groups. Additionally, a significant majority of the participants did not have the dose or method of administration recorded for their estrogen therapy.

Data suggest a positive correlation between estrogen use and VTE. A recent review found the overall incidence rate to be 2.3 events per 1,000 patient-years.41 While this is a significant increase in risk, the absolute risk remains relatively low and often does not dissuade patients from initiating feminizing hormone therapy.

**Conclusion**

While data on VTE risk in trans feminine individuals on hormone therapy are underdeveloped, there are several important clinical lessons to be learned. Clinicians should avoid the use of ethinyl estradiol as it has a significantly higher risk for VTE than other formulations of estrogen. Avoiding ethinyl estradiol might make the use of hormone therapy in trans
<table>
<thead>
<tr>
<th>Study</th>
<th>Sample size</th>
<th>VTE (%)</th>
<th>Hormone dose and route associated with VTE</th>
<th>Additional VTE risk factors</th>
<th>Age of sample (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aschemann et al (1989)</td>
<td>303</td>
<td>6.3</td>
<td>0.05 mg ethinyl estradiol bid+50 mg bid cyproterone acetate</td>
<td>Age&gt;40 years (VTE in 2.1% under age 40 vs 12% in over age 40) Smoking Hypercholesterolemia</td>
<td>32 (median)</td>
</tr>
<tr>
<td>Wierckx et al (2012)</td>
<td>50</td>
<td>2</td>
<td>0.625 mg conjugated estrogens (n=1)</td>
<td>Smoking Hypercholesterolemia Hypertension</td>
<td>52 (age of patient with VTE)</td>
</tr>
<tr>
<td>Wierckx et al (2013)</td>
<td>214</td>
<td>5.1</td>
<td>17β-estradiol gel, 1.5 mg/24u (n=76; VTE n=3) 2 mg estradiol valerate (n=91; VTE n=4) 50 µg ethinyl estradiol (n=2; VTE n=1) 0.625 conjugated equine estrogen (VTE n=1) Cyproterone acetate (VTE n=1) Unknown (VTE n=1)</td>
<td>Smoking Hypercholesterolemia Hypertension Surgery/immobilization Clotting disorder</td>
<td>48 (mean)</td>
</tr>
<tr>
<td>van Kesteren et al (1997)</td>
<td>816</td>
<td>5.5</td>
<td>100 µg ethinyl estradiol+100 mg cyproterone acetate daily (VTE n=40) Transdermal 17β-estradiol (VTE n=1)</td>
<td>Suicide AIDS COPD Malignancies</td>
<td>41 (mean)</td>
</tr>
<tr>
<td>Prior (1989)</td>
<td>61</td>
<td>0</td>
<td>Premarin 2.5 mg/day</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Dittrich (2005)</td>
<td>60</td>
<td>1.7</td>
<td>Estradiol 2–4 mg/day+GnRH analog 1×/month (VTE n=1)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Wilson et al (2009)</td>
<td>30</td>
<td>0</td>
<td>Premarin 2.5 mg/day (n=23) Transdermal estradiol+cyproterone acetate or finasteride (n=7)</td>
<td>–</td>
<td>36 (oral estrogen group)</td>
</tr>
<tr>
<td>Schlatterer (1998)</td>
<td>46</td>
<td>0</td>
<td>Estrogen esters IM 100 mg/2 weeks Cyproterone acetate 100 mg/day 2 patients were on unknown estrogen</td>
<td>Clotting history Nicotine Cardiovascular disorders BMI</td>
<td>47 (transdermal estradiol group)</td>
</tr>
<tr>
<td>Ott et al (2010)</td>
<td>162</td>
<td>0</td>
<td>Transdermal estrogen 0.1 mg 2×/week Cyproterone acetate 50 mg/day Finasteride 5 mg every other day</td>
<td>Clotting history Smoking Hypertension Hypercholesterolemia</td>
<td>36.6</td>
</tr>
<tr>
<td>Cuypere (2011)</td>
<td>32</td>
<td>0</td>
<td>2 mg estradiol+50 mg cyproterone acetate/day</td>
<td>Hypertension (n=1) Depression (n=8) Diabetes (n=2)</td>
<td>37.8</td>
</tr>
</tbody>
</table>

(Continued)
feminine individuals safer than birth control. Additionally, data in both cis and trans groups suggest an additional VTE risk associated with the use of progestins, which would suggest they be avoided when working with transgender individuals. Ethinyl estradiol has largely been abandoned as a form of hormone therapy; however, current data do not offer more specific insight into how to quantify cardiovascular risk. Although there seems to be clear evidence that transdermal estrogens dosed up to 0.1 mg/day or below are a lower risk for VTE than other forms of estrogen, it is unclear whether this is related to the delivery method or a dose effect. Risk mitigation is an important part of the care of transgender patients due to the many risks associated with not providing hormone therapy (ie, poor mental health) and the potential risks associated with hormone therapy. Further study of the relationship between estrogen and the risk of VTE will serve to inform the safest possible care for transgender patients.

Disclosure

Dr Joshua D Safer was a member of an Advisory Board for Endo Pharmaceuticals, June, 2018. The authors report no other conflicts of interest in this work.

References


